ArticleAsia-Pacific journal of clinical oncology2026
Outcomes for Patients With Micro-Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District.
Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to review the outcomes for patients with microinvasive and small HER2+ breast cancers, compare the clinicopathological features, and explore the patterns of care.
methodsIn this single-center retrospective study, patients with HER2+, pT1mic-bN0M0 disease who underwent surgery in Northern Sydney Local Health District between 2006 and 2022 were selected. The primary outcome was invasive disease-free survival (iDFS), and secondary outcome was overall survival (OS).
resultsOf the 32 eligible patients, those with pT1b disease had higher histological grades and Ki-67 indices, with a higher rate of trastuzumab administration. One recurrence and one death were observed in the pT1a group. The 5-year iDFS and OS were 93% for the pT1mic/a group and 100% for the pT1b group (p = 0.29). Sixty-six percent of patients received adjuvant trastuzumab. Trastuzumab prescription was associated with larger tumor sizes (p = 0.008) and higher histologic grades (p = 0.023).
conclusionsPatients with microinvasive or small HER2+ node-negative breast cancer experience favorable outcomes. The pT1b group had higher histological grades and proliferative indices. Patients with pT1b disease or higher tumor grades were more likely to receive trastuzumab. While trastuzumab is recommended for pT1b disease with strong evidence, its use in pT1a disease should be balanced against its unclear benefits and known toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.